University of Patras
Μελέτη της στόχευσης του συστήματος υαλουρονικού/CD44 στον καρκίνο
Abstract
dc:descriptionThe present thesis highlights the importance of targeting hyaluronan network in the development of more efficient therapeutic approaches against aggressive cancer (sub)types, such as triple negative breast cancer and gliomas. Breast cancer is characterized by high heterogeneity and can be classified based on the presence or absence of Estrogen Receptor α (ERα), Progesterone Receptor (PgR), and Human Epidermal Growth Factor Receptor 2 (HER2). The majority of breast cancer cases (~70%) express ERα and are associated with good prognosis due to the availability of effective hormonal therapies. On the other hand, breast cancer subtypes that do not express ERα (such as Triple Negative Breast Cancers, ERα-/PgR-/HER2-) are characterized by increased aggressiveness and poor prognosis. Glioma is the most common type of brain tumors in adults, accounting for 78% of brain cancers. The most aggressive form of gliomas is glioblastoma multiforme, which is considered the most prevalent primary brain cancer. Most patients with this disease die within a year of diagnosis despite multimodal treatment, due to the heterogeneity of the disease, its invasive nature, and its ability to resist chemotherapy. Hyaluronan is an unbranched heteropolysaccharide and constitutes one of the most important multifunctional components of the extracellular matrix. Its biosynthesis occurs at the cell membrane by hyaluronan synthase isoenzymes (HAS1, HAS2, and HAS3). Hyaluronan exerts its effects through interactions with cell surface receptors, such as the CD44 glycoprotein. The binding of hyaluronan to CD44 is a critical molecular interaction that regulates various physiological and pathological processes, including cancer. Given the significant role of hyaluronan network (hyaluronan synthases, hyaluronidases, and hyaluronan receptors) in cancer, the present PhD thesis focused on limiting the actions of the network by either hyaluronan biosynthesis inhibition or by preventing its binding to CD44. Previous studies by our research team have shown that the suppression of hyaluronan biosynthesis using 4-methylumbelliferone (4-MU) or salicylate (SA) significantly reduces the growth of metastatic breast cancer cells. To further investigate the underlying molecular mechanisms, the effect of these inhibitors on the production of intracellular ROS and oxidative stress-related factors, such as the transcription factor NRF2 and its target genes, was examined. Additionally, the impact of hyaluronan inhibitors on ribosomal protein S6 (rpS6) was studied. rpS6 is a critical component of the 40S ribosomal subunit and is activated through phosphorylation in response to various mitogens. Phosphorylated (active) rpS6 plays a significant role in ribosome biogenesis and assembly, protein synthesis, cell cycle regulation and proliferation. The results showed that the suppression of hyaluronan biosynthesis (using 4-MU or SA) in metastatic triple-negative breast cancer cells induced intracellular ROS production while affected the subcellular distribution of NRF2 and the expression of its target genes. At the same time, it inhibited the activation of the mTOR signaling pathway and the phosphorylation-activation of rpS6. The observed reduction in rpS6 activation was accompanied by a significant decrease in cancer cell proliferation and growth, as 4-MU treatment induced cell cycle arrest, as demonstrated by FACS analysis and the reduced levels of cyclin D1, a key regulator of cell cycle progression. Exogenously added hyaluronan did not counteract the effect of 4-MU on rpS6 phosphorylation, indicating the crucial role of endogenous hyaluronan. Silencing of the HAS2 gene, which is the primary hyaluronan synthase in metastatic breast cancer cells, led to decreased rpS6 phosphorylation, consistent with the results of hyaluronan biosynthesis inhibition using 4-MU, highlighting the direct correlation between hyaluronan and the biological actions of rpS6.Hyaluronan is also the main glycosaminoglycan of the central nervous system, while CD44 is overexpressed in more than 50% of glioblastoma multiforme cases. The interactions between hyaluronan and CD44 seem to drive the progression of this brain cancer type. In this thesis, we also examined the interaction of hyaluronan with the CD44 receptor and the signaling through EGFR. Initially, novel macrocyclic peptides were synthesized and their binding to the hyaluronan-binding region of CD44 was investigated. Two of these peptides (L4-3 and D4-3) exhibited strong binding affinity to CD44. L4-3 and D4-3 significantly inhibited the adhesion of U251MG glioblastoma cancer cells to hyaluronan substrate and critically affected signaling pathways that regulate the functional properties of U251MG glioblastoma cells. Specifically, the L4-3 peptide enhanced the PMA-induced reduction of EGFR phosphorylation (at the Tyr1068 residue) and decreased the EGF-induced phosphorylation of the AKT protein. In summary, this PhD thesis demonstrates the significant role of the hyaluronan-CD44 axis in cell signaling and the behavior of various cancer types. These findings suggest that targeting hyaluronan biosynthesis and its interactions could contribute to the treatment of different types of cancer, which are characterized by increased biosynthesis and accumulation of hyaluronan.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chatzopoulos, Athanasios
- Χατζόπουλος, Αθανάσιος
Subjects
dc:subject × 20- Καρκίνος του μαστού
- Πολύμορφο γλοιοβλάστωμα
- Υαλουρονικό
- CD44
- HAS2
- Ριβοσωμική πρωτεΐνη S6
- 4-ΜU
- Μακροκυκλικά πεπτίδια
- Breast cancer
- Glioblastoma multiforme
- Ηyaluronan
- Ribosomal protein S6
- 4-MU
- Macrocyclic peptides
- Βιολογία
- Φυσικές Επιστήμες
- Βιοχημεία και Μοριακή βιολογία
- Biological Sciences
- Natural Sciences
- Biochemistry and Molecular Biology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58715